Uganda and the Democratic Republic of the Congo (DRC) are at the centre of a significant scientific breakthrough as researchers advance the world’s first human clinical trial of a vaccine specifically developed against the Bundibugyo strain of the Ebola virus. Led by the University of Oxford and international research partners, the Phase I study marks the first time a vaccine targeting this Ebola variant has been administered to volunteers. The milestone comes as health authorities continue responding to the ongoing outbreak affecting parts of Central Africa while reinforcing disease surveillance, regional cooperation and public health preparedness.
For the travel and tourism industry, the vaccine trial represents progress in medical research rather than an indication of immediate changes to international travel. Uganda has officially declared its recent outbreak over after completing the required monitoring period, while response efforts remain concentrated in affected areas of the DRC. Airlines, governments and international health agencies continue maintaining essential transport links alongside public health measures.
World’s First Human Trial Targets the Bundibugyo Ebola Strain
The new BD-Ebov Phase I clinical trial is the first human study designed specifically to evaluate a vaccine against the Bundibugyo ebolavirus.
Conducted by the University of Oxford’s Oxford Vaccine Group, the study will assess the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adult volunteers. The vaccine uses the same ChAdOx1 platform that supported the Oxford–AstraZeneca COVID-19 vaccine, enabling researchers to accelerate development in response to the ongoing outbreak.
The first volunteer received the vaccine in July 2026, marking an important milestone in global efforts to combat this specific Ebola strain.
Uganda and DRC Continue Regional Health Cooperation
The outbreak has reinforced the importance of cross-border collaboration between Uganda and the Democratic Republic of the Congo.
While Uganda recently declared its Bundibugyo Ebola outbreak over after completing the World Health Organization’s recommended 42-day observation period without new cases, authorities continue supporting regional surveillance and preparedness because of the much larger outbreak in neighbouring eastern DRC.
Health agencies remain focused on case detection, laboratory testing, contact tracing and community engagement to help contain transmission in affected regions.
Scientific Innovation Supports Long-Term Travel Confidence
Although vaccine development is primarily a public health initiative, it also contributes to long-term confidence in international travel.
Strong disease surveillance systems, rapid scientific research and coordinated outbreak responses help strengthen resilience across destinations that depend on aviation, tourism and cross-border mobility.
For travellers, the latest clinical trial demonstrates the increasing ability of international research institutions and health authorities to respond quickly to emerging infectious diseases through scientific collaboration.
The programme also illustrates the importance of preparedness in protecting both local communities and international connectivity.
Tourism Continues Outside Affected Areas
The current outbreak remains concentrated in specific affected regions rather than across the entirety of Central Africa.
There have been no broad international travel restrictions affecting tourism throughout Uganda, and the country continues welcoming visitors to destinations including Bwindi Impenetrable National Park, Queen Elizabeth National Park, Murchison Falls National Park and Lake Victoria, subject to official travel advice issued by individual governments.
Travellers are encouraged to follow guidance from national health authorities and foreign ministries before travelling, particularly when visiting regions close to active public health responses.
Global Partnerships Accelerate Vaccine Development
The rapid progression of the vaccine programme reflects unprecedented international collaboration.
Researchers from the University of Oxford are working alongside the Coalition for Epidemic Preparedness Innovations (CEPI) and the Serum Institute of India, which has already manufactured investigational doses to support clinical evaluation and potential future deployment if the vaccine proves successful.
Preparations are also underway for additional studies in Uganda, subject to regulatory approvals and trial outcomes.
Health Security Strengthens Future Tourism
Public health preparedness increasingly forms part of tourism resilience worldwide.
Investment in disease surveillance, laboratory capacity, vaccine research and emergency response systems helps destinations respond more effectively to health challenges while supporting long-term visitor confidence.
For African tourism, advances in scientific innovation reinforce the continent’s commitment to strengthening health systems alongside economic development and international connectivity.
Key Stats
- World’s first Phase I human trial targeting the Bundibugyo Ebola virus has commenced.
- 50 healthy volunteers are participating in the Oxford-led Phase I study.
- Uganda has officially declared its recent Bundibugyo Ebola outbreak over following the required monitoring period.
- Preparations are underway for future clinical studies in Uganda, subject to regulatory approval.
Practical Travel Information
Region: Central Africa
Nearest International Airports:
- Entebbe International Airport (Uganda)
- N’Djili International Airport, Kinshasa (DRC)
Nearby Attractions in Uganda:
- Bwindi Impenetrable National Park
- Queen Elizabeth National Park
- Murchison Falls National Park
- Kibale National Park
- Lake Victoria
- Source of the Nile, Jinja
Local Currencies:
- Uganda: Ugandan Shilling (UGX)
- Democratic Republic of the Congo: Congolese Franc (CDF)
Frequently Asked Questions
1. What is the Bundibugyo Ebola vaccine trial?
It is the world’s first Phase I human clinical trial evaluating a vaccine specifically developed against the Bundibugyo strain of the Ebola virus.
2. Does the vaccine trial affect international travel?
No. The clinical trial is a scientific development and does not itself change international travel requirements. Travellers should continue following official health and travel advisories.
3. Has Uganda’s Ebola outbreak ended?
Yes. Uganda officially declared its recent Bundibugyo Ebola outbreak over after completing the required 42-day monitoring period without new cases.
Timeline and Events
- 13 July 2026: University of Oxford launches the world’s first Phase I Bundibugyo Ebola vaccine trial.
- 24 July 2026: First volunteer receives the experimental Bundibugyo Ebola vaccine.
- 28 July 2026: Uganda officially declares its Ebola outbreak over after meeting WHO monitoring requirements.
Dates
13 July 2026 – Phase I Bundibugyo Ebola Vaccine Trial Launched
24 July 2026 – First Volunteer Vaccinated
28 July 2026 – Uganda Declares Recent Ebola Outbreak Over
Conclusion
The launch of the world’s first clinical trial for a Bundibugyo Ebola vaccine represents a significant advance in global public health and disease preparedness. While response efforts continue in affected areas of the Democratic Republic of the Congo, Uganda’s successful containment of its recent outbreak and continued regional cooperation demonstrate the importance of coordinated surveillance and scientific innovation. For the travel and tourism sector, these developments reinforce long-term confidence in health security, highlighting how research, international partnerships and effective public health systems contribute to resilient and sustainable tourism across Central Africa.
